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Abstract
Background: Glioma is the most common malignant primary brain tumor among adults, among which glioblastoma
(GBM) exhibits the highest malignancy. Despite current standard chemoradiation, glioma is still invariably fatal. A further
insight into the molecular background of glioma is required to improve patient outcomes.
Method: Previous studies evaluated molecular genetic differences through comparing different grades of glioma. Here,
we integrated DNA methylation, RNA sequencing and protein expression data sets of WHO grade II to IV gliomas, to
screen for dysregulated genes in subtypes during malignant progression of glioma.
Results: We propose a list of universal genes (UG) as novel glioma biomarkers: 977 up-regulated genes and 114
down-regulated genes, who involved in cell cycle, Wnt receptor signaling pathway and fatty acid metabolic process.
Poorer survival was associated significantly with the high expression of 977 up-regulated genes and low expression of
114 down-regulated in UG (P <0.001).
Conclusion: To our knowledge, this was the first study that focused on subtypes to detect dysregulated genes
that could contribute to malignant progression. Furthermore, the differentially expressed genes profile may lead
to the identification of new therapeutic targets for glioma patients.
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Introduction
Glioma is the most common malignant primary brain
tumor among adults [1, 2]. The tumors are graded on a
WHO consensus-derived scale of I to IV according to
their degree of malignancy, as judged by various histo-
logical features [3, 4]. Astrocytic tumors, which are the
most common group of human gliomas, have an inherent
tendency for recurrence and malignant progression, and
usually cannot be cured by neurosurgical resection, radio-
therapy and/or chemotherapy [5]. Regardless of treatment
strategy, the majority of patients of low grade gliomas
undergo recurrence or malignant transformation over
time, and most patients eventually succumb to the disease.
The 5-year progression rate of low grade gliomas was
between 50 and 70 %, and malignancy-free survival rate of
low grade gliomas was between 30 and 70 % [6, 7]. Relative
survival estimates for glioblastoma are quite low. Only
5.0 % of patients survived five years after diagnosis [8].
Despite recent advances in cancer diagnosis and treatment,
these statistics have not changed significantly. GBM still
remains one of the most challenging cancers in clinical
oncology [9].
Therefore, it is essential to investigate the mechanism
involved in the development and progression of glioma.
The Cancer Genome Atlas (TCGA) described a robust
gene expression-based molecular classification of GBM
into Proneural, Neural, Classical and Mesenchymal sub-
types [10]. After that, TCGA indicated the existence of a
glioma-CpG island methylator phenotype (G-CIMP). G-
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CIMP tumors, a subgroup of Proneural subtype, were more
prevalent among lower-grade gliomas, displayed distinct
copy-number alteration and were tightly associated with
IDH1 somatic mutations [11]. IDH1 mutation, somatic
mutation in isocitrate dehydrogenase 1 gene, occurs at high
frequency in gliomas and seems to be a prognostic factor in
glioblastoma patients [12–14]. Patients with G-CIMP
tumors were younger at the time of diagnosis and had sig-
nificantly improved outcome [15]. The GBM phenotype is
ultimately a product of a set of processes, each prone to
selective pressure and dysregulation in cancer. Selective
pressure is accepted as a driving force behind cancer-
associated remodelling of the genome, epigenome and
proteome.
Previous studies evaluated molecular genetic differences
through comparing different grades of glioma [16–18].
But the differences might be due to the different expres-
sion subtype, whose composition varied among grades.
Here, we integrated DNA methylation, RNA sequencing
and protein expression data sets of WHO grade II to IV
glioma, to screen for dysregulated genes in subtypes dur-
ing malignant progression. We found genes that could act
universally in all subtypes of gliomas. Such an integrative
approach is crucial for the identification of promising
targets and the correponding therapies.
Material & methods
Patients and samples
High throughput data (DNA methylation, RNA sequencing
and protein expression), molecular pathological data (IDH
mutation) and clinical characteristics of astrocytic glioma
patients (astrocytoma (A), anaplastic astrocytoma (AA)
and glioblastoma multiforme (GBM)) were downloaded
from The Cancer Genome Atlas (TCGA, http://cancergen-
ome.nih.gov/). There were 195 samples in the methylation
data; 340 samples in the RNAseq data and 149 samples in
the protein expression data. The RNA sequencing data
were log2 transformed before the following analysis.
TCGA subtype annotation
TCGA subtypes were classified according to the Proneural-
Neural-Classical-Mesenchymal classes using the signatures
published in Verhaak et al. and single sample Gene Set
Enrichment Analysis algorithm (ssGSEA) Glioma-CpG
island methylator phenotype (G-CIMP) tumors were
defined as IDH mutated proneural ones. The gliomas
were classified into five different subtypes: G-CIMP-
positive (IDH-mutated) proneural, G-CIMP-negative
(IDH-wild-type) proneural, classical, mesenchymal and
neural tumors.
Differential analysis/Data mining
Significance analysis of microarrays (SAM) was applied
to identify differentially methylated or expressed genes
between two groups [19]. Because of the limited gene
count in protein expression, the t test was used to deter-
mine differences in each two group comparison.
Functional annotation
Gene Ontology (GO) analysis of differentially expressed
genes was performed in DAVID (http://david.abcc.n-
cifcrf.gov/). Gene Set Enrichment Analysis (GSEA) was
used to further validate the functional enrichment of
those genes [20].
Statistical analysis
Kaplan–Meier survival analysis was used to estimate the
survival distributions, and the log-rank test was used to




292 RNAseq data from TCGA samples (A, AA, GBM)
were downloaded and were classified according to TCGA
subtype signatures published by Verhaak et al. [21]. The
proneural samples were futher classifed into G-CIMP-
positive (IDH-mutated) proneural and G-CIMP-negative
(IDH-wild-type) proneural accoding to IDH1/2 mutation
status (Fig. 1). Because the limited number of neural and
mesenchymal samples did not meet the threshold for
statitical analysis, we focused on classical, IDH-mutated
proneural and IDH-wild-type proneural subtypes in the
following analysis. The sample size was listed in Table 1.
Genes universally contribute to malignant progression in
three subtypes
We analyzed DNA methylation data and RNAseq data to
find out differentially expressed genes that could universally
contribute to malignant progression in three subtype. We
used SAM to filter the high throughput data. Those genes
were supposed to meet these following criteria: 1) dif-
ferentially methylated and expressed between A and
AA in three subtype (FDR < 0.05); 2) differentially methyl-
ated and expressed between A and GBM in three subtype
(FDR < 0.05); 3) there was a negative correlation between
its methylation and expression (Pearson’s correlation p
value <0.05, r < 0).
The 1091 differentially expressed genes, containing 977
up-regulated and 114 down-regulated, were called universal
genes (UG). Of the 172 genes with protein expression data,
9 genes (BRAF, RAF1, PDK1, BAK1, CCNE2, FN1, GATA3,
IGFBP2, CCNB1) were differently expressed in protein
level.
The data were incorporated into a symmetrically divided
hexagon, with color-encoded values for AA in the top
quadrants and with corresponding values for the GBM in
the bottom sections, as depicted in Fig. 2a. By this
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arrangement, the top and bottom halves of the hexagon
represent mirror images of the DNA, RNA and protein
measures for the AA and GBM, respectively.
In order to facilitate the recognition and visualization
of genetically linked trends across tumours and grafts,
an omic map was assembled in which 3273 hexagons
(1091 genes × 3 subtypes) were assembled into an array
by ordering horizontally according to 3 subtypes, and as a
linear genetic map in the vertical direction (Fig. 2b and c).
Gene Ontology analysis was performed by DAVID to
infer the function of the differentially expressed genes. One
hundred twenty-four up-regulated genes were enriched
(P < 0.05 and FDR < 0.05) in cell cycle (Table 2). GSEA
further validated the cell cycle association of the up-
regulated genes in every subtype (Fig. 3). The down-
regulated genes were enriched in Wnt receptor signaling
pathway and fatty acid metabolic process.
Prognostic validation of universal genes in TCGA and
external dataset
We examined prognostic value of UG on survival. The
1091 genes whose expression more strongly correlated
with grade from TCGA database were used as markers
to cluster 511 TCGA GBM samples for kmeans cluster-
ing (k = 2) [22, 23]. The prognosis of patients in group2
(highly expressed in up-regulated UG) (median: 386 days)
was poorer than those in group1 (highly expressed in
down-regulated UG) patients (median: 447 days, p =
0.0095) (Fig. 5a).
Next, we employed 310 glioma samples from the Chinese
Glioma Genome Atlas (CGGA, http:// www.cgga.org.cn/)
Table 1 Molecular pathology features of DNA methylation,
RNAseq and protein expression samples
Database DNA methylation RNAseq Protein expression
Histology A AA GBM A AA GBM A AA GBM
Total Number 20 35 112 48 96 151 22 47 58
Proneural IDH (+) 2 2 10 11 21 9 2 3 4
Proneural IDH (-) 13 12 16 23 35 16 13 24 10
Classical 3 18 86 8 36 89 4 18 44
Mesenchymal 0 3 0 1 4 30 0 1 0
Neural 2 0 0 3 2 7 3 1 0
Fig. 1 TCGA subtype annotation. Using the predictive 840 gene list, samples were ordered on the basis of subtype predictions
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to validate the association between universal genes and
overall survival using Kaplan–Meier survival curve (Fig. 4).
The up-regulated UG were highly expressed in group
1 and 3, while down-regulated UG were highly expressed
in group 2 and 4. There was a significant difference
among the four groups. The OS was short in group1
(median: 447 days) and group 3 (median follow-up:
439 days). The median OS was un-reached in group 2
and group 4. Patients with high expression up-regulated
UG indicated a significantly poor survival than those
with high expression down-regulated UG (p < 0.0001)
(Fig. 5b). Up-regulated UG expressed higher in Group1
than group3, and down-regulated UG expressed higher
Fig. 2 An integrated omic platform for the characterization of glioma patients in three subtypes. a A, AA and GBM were quantified for DNA methylation,
RNAseq and protein expression. Data for each primary GBM and AA, relative to A, were color-encoded as indicated and integrated into six-sided polygons
in a symmetrical manner, with AA data in the top three quadrants, and data from the GBM in the mirror-image bottom sections. b The
polygons were assembled as a linear genetic map in the vertical direction, which organized by chromosome and by three subtypes in
the horizontal direction: IDH-wild-type (IDH-WT) Proneural, IDH-mutated (IDH-Mut) Proneural, Classical. c By this approach 1091 data points were integrated
into 3273 polygons. These reflected correlated changes in one or more of the linked genes across the set of individual AA and GBM. Red, high expression;
Blue, low expression; White, not significant difference; Grey, data not available
Table 2 Top four GO terms of the 43 genes
GO term Biological process Gene count p-value
GO:0007067 mitosis 34 1.44E-07
GO:0000280 nuclear division 34 1.44E-07
GO:0000087 M phase of mitotic cell cycle 34 2.21E-07
GO:0000279 M phase 43 3.11E-07
GO gene ontology
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in group 2 than group 4 (Fig. 4). The results was concord-
ant with the trend of survival curves, where the prognosis
of these patients in group3 and group 2 were better than
those in group1 and group4, respectively (Fig. 5b). How-
ever, the differences did not reach statistical significance.
GBM (WHO grade IV) patients were mainly enriched in
group1 and group2, while group2 and group4 showed
highly association with oligodendroglioma (WHO grade
II) and astrocytoma (WHO grade II).
To further confirm the result, we clustered the GBM
samples in CGGA database by differentially expressed
genes. The GBM samples were separated into 2 groups.
High expression down-regulated UG also showed a better
prognosis in patients (p = 0.0365) (Fig. 5c).
Discussion
It is clear that GBM represents a heterogeneous type of
neoplasm when considering its molecular and genetic
features [24]. The integration of comprehensive data sets
spanning the sequence to phenotype continuum DNA-
RNA-protein-disease covered molecular signatures linking
cancer progression and overall survival in glioma. Gliomas
have been analyzed by several groups with the use of vari-
ous types of large-scale methods. Low-grade astrocytomas
(WHO grade 2), which account for approximately 35 % of
human astrocytic tumors, generally affect young people
with a mean age of 39 years. The most common chromo-
somal alteration seen in low-grade astrocytoma is the
deletion of chromosome band 17p13.1 and mutations of
the tumor suppressor gene p53 (TP53), which reside in
this region [25]. Unlike low-grade astrocytomas, anaplastic
astrocytomas are more cellular, have increased cellular
atypia and have increased cellular proliferation [26]. The
genetic changes associate with the transition from low-
grade to anaplastic astrocytoma included allelic loss of
chromosome arms 9p, 11p, 13q and 19q. Many of the
alterations observe in anaplastic astrocytomas genes that
regulate cell cycle progression. For example, alterations of
the retinoblastoma (Rb) gene map to 13q14 occur in 40 %
of anaplastic patients [18]. Glioblastomas are the most
malignant astrocytic tumor. In addition to cellular atypia,
increased mitotic index and infiltrative growth into adjacent
normal brain, glioblastomas show intratumoral necrosis
and vascular endothelial proliferation. Amplification of the
EGFR locus is found in approximately 40 % of primary
glioblastomas [27]. Mutations of the PTEN gene are
found in 45 % of primary glioblastomas. Mutations of
PTEN lead to constitutive activation of the phosphoti-
dylinositol-3, 4, 5 triphosphate pathway; one member
of this family is Akt. The mechanism of function and
Fig. 3 Gene set enrichment analysis of UG in three subtypes. The cell-cycle enrichment ploted of universally up-regulated genes in (a) IDH-wild-type
Proneural AA, (b) IDH-mutated Proneural AA, (c) IDH Classical AA, (d) IDH-wild-type Proneural GBM (e) IDH-mutated Proneural GBM, (f) IDH Classical GBM
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the role of PTEN in gliomagenesis have been widely
studied [28].
These molecular genetic studied of gliomas detected mo-
lecular abnormalities through comparing different grades.
However, we supposed that the molecular abnormalities
distributed also associated significantly with subtypes.
Here, we presented a particular study which focused on
the same subtype in different grades to find out differen-
tially expressed genes during malignant progression of
glioma. Through this approach we discovered 1091 UG
(977 up-regulated genes and 114 down-regulated genes) in
DNA methylation and RNA sequencing data. The function
of UG were mainly about cell cycle progression. Thus, that
might be a good explanation for why patients with high
expressed UG had a poor prognosis.
Because of the limitation of protein expression database,
we discovered the UG mainly by analyze DNA methylation
and RNA sequencing. After combining genes in protein
expression database, only 9 up-regulated UG were left:
BRAF, RAF1, PDK1, BAK1, CCNE2, FN1, GATA3, IGFBP2,
CCNB1. There were six genes exhibited same tendency in
A to AA and A to pGBM. The BRAF, RAF1, PDK1 had a
lower protein expression in AA and GBM while BAK1,
CCNE2, GATA3 had a higher protein expression. These
data indicate that generally protein abundance may not be
a simple relationship of DNA and mRNA levels, may reflect
Fig. 4 K-means clustering identified four groups of 310 CGGA samples by UG. K-means clustering identified of 310 CGGA samples by 1091 genes
whose expression most strongly correlated with grade from TCGA database for k = 4
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proteome remodelling in response to selective pressure for
an aspect of the tumor phenotype that is manifest at the
protein level.
We summarized 71 prognostic genes signature from
previously papers [29–34]. The overlap of UG signature
and previously genes signature were 19 genes. Most of
the previously genes signature were based on high grade
gliomas. In this paper, we integrated DNA methylation,
RNA sequencing and protein expression data sets of
WHO grade II to IV glioma, to screen for dysregulated
genes, which were more accurate. There were 124 UG
genes enriched (P < 0.05 and FDR < 0.05) in cell cycle.
CCNB1, one of the UG genes, which is a protein essen-
tial for cell cycle progression through the G2/M phase.
CCNB1 was reported as a novel therapeutic approach
against many tumors [35–37] and may become novel
therapeutic target for glioma.
Conclusion
In summary, our study has provided a better understanding
of tumor heterogeneity and disease progression in GBM.
We show that up-regulated UG are a crucial factor for ma-
lignant progression and poor prognosis in glioma patients
and modulate the cell cycle, and that down-regulation of
UG predict a better outcomes in patients. To our know-
ledge, this is the first study that focus on subtypes to detect
dysregulated genes that can contribute to malignant pro-
gression. Furthermore, the differentially expressed genes
profile may lead to the identification of new therapeutic tar-
gets for glioma patients. Although the therapeutic oppor-
tunities for glioma remain limited, continuing efforts to
detail the mechanisms of disease relapse would contribute
to our ability to provide curative treatment for this lethal
disease.
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